Marker Therapeutics (MRKR) announced that it had achieved positive interim results from its phase 1/2 study using MultiTAA to treat patients with pancreatic cancer. This preliminary data points to the potential for MultiTAA to be used as a front-line therapy with chemotherapy and possibly second-line therapy in chemo-refractory patients as well. The biotech has also already done well using MultiTAA to treat multiple types of blood cancer as well. Specifically, it is gearing up in the coming weeks/months in Q3 of 2019 to file an IND to begin a phase 2 study for